Market Closed -
OTC Markets
11:18:05 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1.76
USD
|
-8.81%
|
|
-8.33%
|
-43.95%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
21.99
|
22.87
|
16.27
|
15.26
|
21.76
|
19.54
|
Enterprise Value (EV)
1 |
24.09
|
26.13
|
18.39
|
17.87
|
18.03
|
13.31
|
P/E ratio
|
-13.1
x
|
-9.02
x
|
-10.7
x
|
79.4
x
|
-2.94
x
|
-1.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.07
x
|
0.7
x
|
0.42
x
|
0.39
x
|
0.54
x
|
0.39
x
|
EV / Revenue
|
1.17
x
|
0.8
x
|
0.47
x
|
0.46
x
|
0.44
x
|
0.27
x
|
EV / EBITDA
|
-17.4
x
|
-66.5
x
|
-31.4
x
|
-20.5
x
|
-7.61
x
|
9.02
x
|
EV / FCF
|
-
|
9,541,840
x
|
22,315,627
x
|
-9,512,444
x
|
-26,532,030
x
|
-17,786,509
x
|
FCF Yield
|
-
|
0%
|
0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
102
x
|
-10.9
x
|
-9.46
x
|
39.4
x
|
2.86
x
|
0.74
x
|
Nbr of stocks (in thousands)
|
2,156
|
2,181
|
2,429
|
2,724
|
3,347
|
6,223
|
Reference price
2 |
10.20
|
10.48
|
6.700
|
5.600
|
6.500
|
3.140
|
Announcement Date
|
1/13/21
|
1/13/21
|
10/12/21
|
4/7/22
|
3/30/23
|
4/11/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
20.64
|
32.63
|
38.94
|
38.85
|
40.6
|
49.73
|
EBITDA
1 |
-1.384
|
-0.3931
|
-0.5856
|
-0.8703
|
-2.369
|
1.476
|
EBIT
1 |
-1.543
|
-0.851
|
-1.147
|
-1.245
|
-2.579
|
-0.124
|
Operating Margin
|
-7.48%
|
-2.61%
|
-2.95%
|
-3.2%
|
-6.35%
|
-0.25%
|
Earnings before Tax (EBT)
1 |
-1.628
|
-2.503
|
-1.443
|
0.218
|
-6.444
|
-19.42
|
Net income
1 |
-1.63
|
-2.506
|
-1.45
|
0.218
|
-6.445
|
-19.42
|
Net margin
|
-7.9%
|
-7.68%
|
-3.72%
|
0.56%
|
-15.87%
|
-39.04%
|
EPS
2 |
-0.7796
|
-1.163
|
-0.6274
|
0.0705
|
-2.214
|
-2.364
|
Free Cash Flow
|
-
|
2.738
|
0.8242
|
-1.878
|
-0.6794
|
-0.7481
|
FCF margin
|
-
|
8.39%
|
2.12%
|
-4.83%
|
-1.67%
|
-1.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/13/21
|
1/13/21
|
10/12/21
|
4/7/22
|
3/30/23
|
4/11/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2.1
|
3.26
|
2.12
|
2.61
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
3.73
|
6.23
|
Leverage (Debt/EBITDA)
|
-1.519
x
|
-8.282
x
|
-3.619
x
|
-2.999
x
|
-
|
-
|
Free Cash Flow
|
-
|
2.74
|
0.82
|
-1.88
|
-0.68
|
-0.75
|
ROE (net income / shareholders' equity)
|
-
|
245%
|
72.9%
|
-32.7%
|
-161%
|
-114%
|
ROA (Net income/ Total Assets)
|
-
|
-7.87%
|
-7.12%
|
-7.16%
|
-11.3%
|
-0.27%
|
Assets
1 |
-
|
31.83
|
20.36
|
-3.044
|
57.28
|
7,315
|
Book Value Per Share
2 |
0.1000
|
-0.9600
|
-0.7100
|
0.1400
|
2.280
|
4.270
|
Cash Flow per Share
2 |
0.0400
|
0.3500
|
0.8600
|
0.5200
|
2.010
|
1.270
|
Capex
1 |
0.14
|
0.04
|
0.67
|
0.12
|
0.19
|
0.77
|
Capex / Sales
|
0.69%
|
0.11%
|
1.72%
|
0.32%
|
0.46%
|
1.55%
|
Announcement Date
|
1/13/21
|
1/13/21
|
10/12/21
|
4/7/22
|
3/30/23
|
4/11/24
|
|
1st Jan change
|
Capi.
|
---|
| -43.95% | 10.98M | | -12.86% | 8.57B | | +32.95% | 1.32B | | +6.76% | 419M | | +5.93% | 282M | | +10.56% | 224M | | -8.26% | 85.07M | | +20.94% | 59.57M |
Retail - Drugs without Grocery
|